Strategies for ADC bioanalysis: an interview with Andy Xue

Antibodies | ADCs Interviews

During the American Association of Pharmaceutical Scientists (AAPS) PharmSci 360 2025 conference, Bioanalysis Zone caught up with industry experts across numerous disciplines to discuss their involvement with AAPS and their research. In this interview, we spoke to Andy Xue about the key considerations for developing assays for ADCs, how to ensure scalability and reproducibility, and how Resolian keeps pace with innovations in the field.

Disclaimer: The opinions expressed in this interview are those of the author and do not necessarily reflect the views of Bioanalysis Zone or Taylor & Francis Group.

Interview questions:

  1. Could you start by telling us a bit about your journey into bioanalysis and what drew you to work on complex modalities like ADCs?
  2. What are the key considerations when developing bioanalytical methods for ADCs compared to other modalities like peptides or small molecules?
  3. Your team works across a wide range of modalities. How do strategies differ when developing assays for ADCs versus peptide-drug conjugates (PDCs) or antibody-oligonucleotide conjugates (AOCs)?
  4. How do you ensure scalability and reproducibility of your ADC methods across preclinical and clinical phases?
  5. With next-generation ADCs featuring novel linker technologies and site-specific conjugation, how are you adapting your bioanalytical strategies to keep pace with these innovations?
  6. What’s your philosophy for developing expertise of Resolian’s scientists to keep up with such innovations?

 

Meet the speaker

Andy Xue
Team Lead III
Resolian (PA, USA)

Andy Xue holds an MS in Chemistry and specializes in LC–MS bioanalysis. He serves as a Team Lead III in the LC–MS department at Resolian, guiding a team of scientists focused on solving complex bioanalytical challenges. Andy and his team have supported numerous sponsors in developing bioanalytical assays for clinical development across a wide range of modalities, including small molecules, ADCs, oligonucleotides, peptides and proteins.

View our video library here.

The opinions expressed in this interview are those of the interviewee and do not necessarily reflect the views of Bioanalysis Zone or Taylor & Francis Group.

In association with:

 

About AAPS

American Association of Pharmaceutical Scientists (AAPS) is a non-profit association of more than 7000 scientists and professionals employed in academia, industry, regulatory and other research related to the pharmaceutical sciences worldwide. Its mission is to advance the capacity of pharmaceutical scientists to develop products and therapies that improve global health, which members pursue through four peer-reviewed journals and a variety of events in person and online.

AAPS PharmSci 360 delivers research from across the pharmaceutical continuum, from discovery to delivery, and all stages in between. Thousands of scientists from across the globe converge to discuss cutting-edge breakthroughs, technologies, and techniques in symposia and poster presentations at this science-first event. https://www.aaps.org/pharmsci360.